Carisma Therapeutics, Inc. (CARM) Dividend History

Carisma Therapeutics, Inc. is a biotechnology company focused on developing advanced cell-based immunotherapies, particularly utilizing macrophages to treat cancer and other diseases. Their innovative approach involves engineering immune cells to enhance their ability to target and destroy tumors, with the goal of creating more effective and personalized treatments.

3675 Market Street, Philadelphia, PA, 19104
Phone: (267) 491-6422
Website:

Dividend History

Pay Date Amount Ex Dividend Date Record Date
March 08, 2023 $0.36 03/08/2023 03/07/2023

Company News

  • In-Depth Examination Of 5 Analyst Recommendations For CARISMA Therapeutics

    5 analysts have expressed a variety of opinions on CARISMA Therapeutics (NASDAQ:CARM) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 2 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $7.8, a high estimate of $9.00, and a low estimate of $6.00. Observing a downward trend, the current average is 13.33% lower than the prior average price target of $9.00. Deciphering Analyst Ratings: An In-Depth Analysis An in-depth analysis of recent analyst actions unveils how financial experts perceive CARISMA Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mitchell Kapoor HC Wainwright & Co. Maintains Buy $8.00 $8.00 Mitchell Kapoor HC Wainwright & Co. Maintains Buy $8.00 $8.00 Mitchell Kapoor HC Wainwright & Co. Lowers Buy $8.00 $9.00 Justin Zelin BTIG Announces Buy $6.00 - Mitchell Kapoor HC Wainwright & Co. Lowers Buy $9.00 $11.00 Key ...Full story available on Benzinga.com

    Benzinga
  • The Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 Experts

    In the preceding three months, 4 analysts have released ratings for CARISMA Therapeutics (NASDAQ:CARM), presenting a wide array of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.75, a high estimate of $9.00, and a low estimate of $6.00. A 22.5% drop is evident in the current average compared to the previous average price target of $10.00. Investigating Analyst Ratings: An Elaborate Study A clear picture of CARISMA Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mitchell Kapoor HC Wainwright & Co. Maintains Buy $8.00 - Mitchell Kapoor HC Wainwright & Co. Lowers Buy $8.00 $9.00 Justin Zelin BTIG Announces Buy $6.00 - Mitchell Kapoor HC Wainwright & Co. Lowers Buy $9.00 $11.00 Key Insights: Action Taken: ...Full story available on Benzinga.com

    Benzinga
  • Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates

    CARISMA THERAP (CARM) delivered earnings and revenue surprises of -24.32% and 12.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: DRRX
  • Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    CARISMA THERAP (CARM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Zacks Investment Research
    Featured Companies: AQST
  • Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now

    CARISMA THERAP (CARM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

    Zacks Investment Research
Dividend data last updated 06/07/2025 22:13:30 UTC